{"id":18964,"date":"2022-03-23T08:24:12","date_gmt":"2022-03-23T15:24:12","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18964"},"modified":"2022-03-23T08:24:14","modified_gmt":"2022-03-23T15:24:14","slug":"4d-pharma-announced-positive-interim-data-from-phase-i-ii-study","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/","title":{"rendered":"4D Pharma Announced Positive Interim Data From Phase I\/II Study"},"content":{"rendered":"\n

4D pharma plc (NASDAQ: LBPS) <\/strong>today announced positive interim data from its Phase I\/II study of MRx0518 in combination with MSD\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae.<\/p>\n\n\n\n

Shares Surge<\/h5>\n\n\n\n

Shares of 4D pharma plc surged over 44% in premarket trading following the announcement.\u00a0<\/p>\n\n\n\n

Efficacy Endpoint Met<\/h5>\n\n\n\n

According to the announcement<\/a>, patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion.<\/p>\n\n\n\n

“Today\u2019s results in renal cell carcinoma, meeting the predefined primary efficacy endpoint early in this difficult to treat population, marks another important step forward for MRx0518 and the increasing importance of the microbiome in cancer treatment. Meeting the primary efficacy endpoint for this group is crucial for the future development of MRx0518, and these data are highly informative for our strategy going forward as we determine next steps in RCC.”<\/p>Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma<\/cite><\/blockquote>\n\n\n\n

The ongoing study is being conducted in heavily pre-treated metastatic patients with solid tumors and is being conducted in collaboration with MSD. The primary efficacy endpoint for Part B of the study is more than three out of 30 patients per tumor group achieving clinical benefit, defined as complete response, partial response, or stable disease for at least six months.<\/p>\n","protected":false},"excerpt":{"rendered":"4D pharma plc (NASDAQ: LBPS) today announced positive interim data from its Phase I\/II study of MRx0518 in combination with MSD\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae. Shares Surge Shares of 4D pharma plc surged over 44% in premarket trading following the announcement.\u00a0 Efficacy Endpoint Met According to the announcement, patients with solid tumors that have progressed on… View Article<\/a>","protected":false},"author":3,"featured_media":18965,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,31,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\n4D Pharma Announced Positive Interim Data From Phase I\/II Study - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4D Pharma Announced Positive Interim Data From Phase I\/II Study - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"4D pharma plc (NASDAQ: LBPS) today announced positive interim data from its Phase I\/II study of MRx0518 in combination with MSD\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae. Shares Surge Shares of 4D pharma plc surged over 44% in premarket trading following the announcement.\u00a0 Efficacy Endpoint Met According to the announcement, patients with solid tumors that have progressed on... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-23T15:24:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-23T15:24:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/03\/CancerResearch-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1347\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"4D Pharma Announced Positive Interim Data From Phase I\/II Study\",\"datePublished\":\"2022-03-23T15:24:12+00:00\",\"dateModified\":\"2022-03-23T15:24:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Business\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\",\"url\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\",\"name\":\"4D Pharma Announced Positive Interim Data From Phase I\/II Study - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-03-23T15:24:12+00:00\",\"dateModified\":\"2022-03-23T15:24:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4D Pharma Announced Positive Interim Data From Phase I\/II Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"4D Pharma Announced Positive Interim Data From Phase I\/II Study - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/","og_locale":"en_US","og_type":"article","og_title":"4D Pharma Announced Positive Interim Data From Phase I\/II Study - MarketDepth","og_description":"4D pharma plc (NASDAQ: LBPS) today announced positive interim data from its Phase I\/II study of MRx0518 in combination with MSD\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae. Shares Surge Shares of 4D pharma plc surged over 44% in premarket trading following the announcement.\u00a0 Efficacy Endpoint Met According to the announcement, patients with solid tumors that have progressed on... View Article","og_url":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-03-23T15:24:12+00:00","article_modified_time":"2022-03-23T15:24:14+00:00","og_image":[{"width":1920,"height":1347,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/03\/CancerResearch-1.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"4D Pharma Announced Positive Interim Data From Phase I\/II Study","datePublished":"2022-03-23T15:24:12+00:00","dateModified":"2022-03-23T15:24:14+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Business","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/","url":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/","name":"4D Pharma Announced Positive Interim Data From Phase I\/II Study - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-03-23T15:24:12+00:00","dateModified":"2022-03-23T15:24:14+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/4d-pharma-announced-positive-interim-data-from-phase-i-ii-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"4D Pharma Announced Positive Interim Data From Phase I\/II Study"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18964"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=18964"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18964\/revisions"}],"predecessor-version":[{"id":18966,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18964\/revisions\/18966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/18965"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=18964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=18964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=18964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}